Ten years ago, a group of executives launched Jomed with the thought of challenging the large cardiovascular device companies as a global player. Jomed never quite achieved that goal--though it came close. Now, with an innovative NO-loaded balloon, some former Jomed executives hope to do in interventional neurology what they tried to do in interventional cardiology.
By David Cassak
Five years ago, virtually the only European company given any chance of building an interventional cardiology business that could realistically...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
